Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 163

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 163
---
Property and equipment, net6,846 4,802 Operating lease right-of-use assets787 1,169 Other assets1,399 1,866 Total assets$70,319 $132,423 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$2,159 $5,898 Accrued liabilities14,647 14,306 Operating lease liabilities, current portion268 434 Due to licensor payable (Note 7)— 5,757 Total current liabilities17,074 26,395 Operating lease liabilities, net of current portion565 833 Other liabilities202 — Total liabilities17,841 27,228 Commitments and contingencies (Note 13)Stockholders’ equity:Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and 2023— — Common stock, $0.0001 par value, 300,000,000 shares authorized; 24,680,708 and 24,554,205 shares issued and outstanding as of December 31, 2024 and 2023, respectively2 2 Additional paid-in capital385,114 374,129 Accumulated other comprehensive income16 27 Accumulated deficit(332,654)(268,963)Total stockholders’ equity52,478 105,195 Total liabilities and stockholders’ equity$70,319 $132,423 

The accompanying notes are an integral part of these consolidated financial statements. 

117

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share data and earnings per share amounts)

Year Ended December 31,20242023RevenueProduct sales, net$25,983 $24,354 Total revenue25,983 24,354 Operating expensesSelling, general and administrative36,749 44,549 Research and development 51,030 48,929 Restructuring charges2,638 — Cost of goods sold3,024 2,809 Total operating expenses93,441 96,287 Loss from operations(67,458)(71,933)Other income (expense)Foreign exchange loss(4)(1)Interest income3,925 6,400 Interest expense(154)(231)Total